28288134|t|DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer
28288134|a|Correct control of DNA replication is crucial to maintain genomic stability in dividing cells. Inappropriate re-licensing of replicated origins is associated with chromosomal instability (CIN), a hallmark of cancer progression that at the same time provides potential opportunities for therapeutic intervention. Geminin is a critical inhibitor of the DNA replication licensing factor Cdt1. To properly achieve its functions, Geminin levels are tightly regulated through the cell cycle by ubiquitin-dependent proteasomal degradation, but the de-ubiquitinating enzymes (DUBs) involved had not been identified. Here we report that DUB3 and USP7 control human Geminin. Overexpression of either DUB3 or USP7 increases Geminin levels through reduced ubiquitination. Conversely, depletion of DUB3 or USP7 reduces Geminin levels, and DUB3 knockdown increases re-replication events, analogous to the effect of Geminin depletion. In exploring potential clinical implications, we found that USP7 and Geminin are strongly correlated in a cohort of invasive breast cancers (P<1.01E-08). As expected, Geminin expression is highly prognostic. Interestingly, we found a non-monotonic relationship between USP7 and breast cancer -specific survival, with both very low or high levels of USP7 associated with poor outcome, independent of estrogen receptor status. Altogether, our data identify DUB3 and USP7 as factors that regulate DNA replication by controlling Geminin protein stability, and suggest that USP7 may be involved in Geminin dysregulation during breast cancer progression .Oncogene advance online publication, 13 March 2017; doi:10.1038/onc.2017.21.
28288134	0	4	DUB3	T116,T126	C1451084
28288134	9	13	USP7	T116,T126	C1142946
28288134	14	39	de-ubiquitinating enzymes	T116,T126	C1333282
28288134	48	69	replication inhibitor	T044	C1325319
28288134	70	77	Geminin	T116,T123	C3665616
28288134	79	88	molecular	T080	C1521991
28288134	89	105	characterization	T052	C1880022
28288134	128	141	breast cancer	T191	C0006142
28288134	150	176	control of DNA replication	T045	C1155665
28288134	200	217	genomic stability	T045	C1257825
28288134	221	235	dividing cells	T025	C0230517
28288134	267	285	replicated origins	T086	C0242961
28288134	289	304	associated with	T080	C0332281
28288134	305	328	chromosomal instability	T049	C1257806
28288134	330	333	CIN	T049	C1257806
28288134	350	368	cancer progression	T046	C1947901
28288134	428	452	therapeutic intervention	T061	C0808232
28288134	454	461	Geminin	T116,T123	C3665616
28288134	476	485	inhibitor	T120	C0243077
28288134	493	508	DNA replication	T045	C0598312
28288134	509	525	licensing factor	T116,T123	C1334394
28288134	526	530	Cdt1	T028	C1332742
28288134	567	574	Geminin	T116,T123	C3665616
28288134	575	581	levels	T080	C0441889
28288134	616	626	cell cycle	T043	C0007586
28288134	630	673	ubiquitin-dependent proteasomal degradation	T044	C1523807
28288134	683	708	de-ubiquitinating enzymes	T116,T126	C1333282
28288134	710	714	DUBs	T116,T126	C1333282
28288134	770	774	DUB3	T116,T126	C1451084
28288134	779	783	USP7	T116,T126	C1142946
28288134	792	805	human Geminin	T116,T123	C0676272
28288134	807	821	Overexpression	T045	C1514559
28288134	832	836	DUB3	T116,T126	C1451084
28288134	840	844	USP7	T116,T126	C1142946
28288134	845	854	increases	T169	C0442805
28288134	855	862	Geminin	T116,T123	C3665616
28288134	863	869	levels	T080	C0441889
28288134	878	885	reduced	T080	C0392756
28288134	886	900	ubiquitination	T044	C1519751
28288134	914	923	depletion	T169	C0333668
28288134	927	931	DUB3	T116,T126	C1451084
28288134	935	939	USP7	T116,T126	C1142946
28288134	940	947	reduces	T080	C0392756
28288134	948	955	Geminin	T116,T123	C3665616
28288134	956	962	levels	T080	C0441889
28288134	968	972	DUB3	T028	C1857782
28288134	973	982	knockdown	T063	C2350567
28288134	983	992	increases	T169	C0442805
28288134	993	1014	re-replication events	T045	C1155651
28288134	1043	1050	Geminin	T116,T123	C3665616
28288134	1051	1060	depletion	T169	C0333668
28288134	1122	1126	USP7	T116,T126	C1142946
28288134	1131	1138	Geminin	T116,T123	C3665616
28288134	1168	1174	cohort	T098	C0599755
28288134	1178	1186	invasive	T080	C0205281
28288134	1187	1201	breast cancers	T191	C0006142
28288134	1229	1236	Geminin	T116,T123	C3665616
28288134	1237	1247	expression	T045	C1171362
28288134	1310	1322	relationship	T080	C0439849
28288134	1331	1335	USP7	T116,T126	C1142946
28288134	1340	1353	breast cancer	T191	C0006142
28288134	1364	1372	survival	T169	C0220921
28288134	1389	1392	low	T080	C0205251
28288134	1396	1400	high	T080	C0205250
28288134	1401	1407	levels	T080	C0441889
28288134	1411	1415	USP7	T116,T126	C1142946
28288134	1416	1431	associated with	T080	C0332281
28288134	1432	1444	poor outcome	T033	C3806166
28288134	1461	1478	estrogen receptor	T116,T192	C0034804
28288134	1479	1485	status	T080	C0449438
28288134	1503	1507	data	T078	C1511726
28288134	1517	1521	DUB3	T116,T126	C1451084
28288134	1526	1530	USP7	T116,T126	C1142946
28288134	1547	1571	regulate DNA replication	T045	C1155665
28288134	1587	1594	Geminin	T116,T123	C3665616
28288134	1595	1612	protein stability	T080	C2350440
28288134	1631	1635	USP7	T116,T126	C1142946
28288134	1655	1662	Geminin	T116,T123	C3665616
28288134	1663	1676	dysregulation	T033	C1704258
28288134	1684	1697	breast cancer	T191	C0006142
28288134	1698	1709	progression	T046	C1947901